Abdera Therapeutics

Abdera Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, with research operations in Vancouver, British Columbia. It was launched in 2021 out of adMare BioInnovations with AbCellera as a founding partner and has raised roughly $148 million from investors including Versant Ventures, Foresite Capital, Johnson & Johnson Innovation (JJDC), Qiming Venture Partners USA, RTW Investments and venBio. The company engineers precision radiopharmaceuticals for solid tumours on its proprietary Radio Optimized Vector Engineering (ROVEr) platform, which pairs antibody-derived targeting vectors with potent alpha-emitting radioisotopes such as actinium-225. Its lead candidate, ABD-147, targets delta-like ligand 3 (DLL3) and is in a Phase 1 trial (NCT06736418) in small cell lung cancer and large cell neuroendocrine carcinoma under FDA Fast Track designation; a second program, ABD-320, targets 5T4. Abdera's product is a drug candidate, not software. It runs no developer program and publishes no API, developer portal, API reference, SDK, or machine-readable specification of any kind. As of 2026-09-06 the company's own corporate site at www.abderatx.com was additionally unreachable, returning a Flywheel "Unknown Domain" host error on every path behind a TLS certificate that expired on 2026-07-19.

Abdera Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Radiopharmaceuticals, and Oncology.

2.9/100 minimal Agent 0/100 human only Full breakdown ↓
scored 2026-09-06 · rubric v0.19.0
0 APIs
CompanyBiotechnologyPharmaceuticalsRadiopharmaceuticalsOncologyDrug DevelopmentClinical TrialsLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-06 · rubric v0.19.0
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/abderatherapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Resources

Access & Security 1

Authentication, authorization, and security posture

Company 1

The organization behind the API

Other 1

Properties that don't map to a standard resource type

Source (apis.yml)

apis.yml Raw ↑
aid: abderatherapeutics
name: Abdera Therapeutics
description: Abdera Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California,
  with research operations in Vancouver, British Columbia. It was launched in 2021 out of adMare BioInnovations with AbCellera
  as a founding partner and has raised roughly $148 million from investors including Versant Ventures, Foresite Capital, Johnson
  & Johnson Innovation (JJDC), Qiming Venture Partners USA, RTW Investments and venBio. The company engineers precision radiopharmaceuticals
  for solid tumours on its proprietary Radio Optimized Vector Engineering (ROVEr) platform, which pairs antibody-derived targeting
  vectors with potent alpha-emitting radioisotopes such as actinium-225. Its lead candidate, ABD-147, targets delta-like ligand
  3 (DLL3) and is in a Phase 1 trial (NCT06736418) in small cell lung cancer and large cell neuroendocrine carcinoma under
  FDA Fast Track designation; a second program, ABD-320, targets 5T4. Abdera's product is a drug candidate, not software.
  It runs no developer program and publishes no API, developer portal, API reference, SDK, or machine-readable specification
  of any kind. As of 2026-09-06 the company's own corporate site at www.abderatx.com was additionally unreachable, returning
  a Flywheel "Unknown Domain" host error on every path behind a TLS certificate that expired on 2026-07-19.
url: https://raw.githubusercontent.com/api-evangelist/abderatherapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Radiopharmaceuticals
- Oncology
- Drug Development
- Clinical Trials
- Life Sciences
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- radiopharmaceuticals
- oncology
- drug-development
- clinical-trials
- life-sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.abderatx.com/
- type: SecondaryMarket
  url: https://equityzen.com/company/abderatherapeutics
- type: DomainSecurity
  url: security/abderatherapeutics-domain-security.yml
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 2
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Abdera Therapeutics is a clinical-stage radiopharmaceutical developer whose product is a drug candidate (ABD-147,
    ABD-320), not software — there is no developer program to profile, and the point is moot in any case because its entire
    corporate site at www.abderatx.com now returns a Flywheel "Unknown Domain" 404 on every path, including the root, behind
    a TLS certificate that expired on 2026-07-19.
  evidence:
  - url: https://www.abderatx.com/
    status: 404
  - url: https://abderatx.com/pipeline/
    status: 404
  - url: https://abderatx.com/.well-known/security.txt
    status: 404
  - url: https://abderatx.com/openapi.json
    status: 404
  - url: https://api.github.com/orgs/abderatx
    status: 404
  checked: '2026-09-06'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/abderatherapeutics"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/abderatherapeutics/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/abderatherapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

A second provider on the same verified email joins the account you already have.